Skip to search formSkip to main contentSkip to account menu

rocilinostat

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Histone deacetylase 6 inhibitor ACY1215 ameliorates mitochondrial dynamic and function injury in hepatocytes by activating AMPK signaling pathway in acute liver failure mice.
Acute liver failure (ALF) is often accompanied by dynamic and functional disorders of mitochondria in hepatocytes. The histone… 
2017
2017
Validation of an LC-MS/MS method for simultaneous detection of four HDAC inhibitors - belinostat, panobinostat, rocilinostat and vorinostat in mouse plasma and its application to a mouse…
A sensitive and rapid LC-MS/MS method was developed and validated for the simultaneous quantitation of four HDAC inhibitors… 
2017
2017
[Protective effect of the histone deacetylase inhibitor ACY1215 against brain edema in mice with acute liver failure].
Objective: To investigate the protective effect of ACY1215 (Rocilinostat), a histone deacetylase inhibitor, against brain edema… 
2016
2016
Sensitive method for the determination of rocilinostat in small volume mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice.
A highly sensitive, specific and rapid LC-ESI-MS/MS method has been developed and validated for the quantification of… 
2016
2016
Rational design and diversity-oriented synthesis of peptoid-based selective HDAC 6 inhibitors †
Histone deacetylases (HDACs) catalyze the cleavage of acetyl groups from N-acetyl-lysine residues of histones and non-histone… 
2016
2016
Abstract 1161: A new, therapeutically actionable target for the VHL E3 ubiquitin ligase in renal cell carcinoma
Background: Loss of function of the von Hippel Lindau (VHL) tumor suppressor is a nearly ubiquitous feature of clear cell renal… 
2014
2014
Preclinical Screening of the HDAC6 Inhibitor Rocilinostat (ACY-1215) Combined with Bendamustine in Lymphoma Cell Lines
Background and Purpose. Histone deacetylase (HDAC) inhibitors are emerging as an exciting new therapeutic option for lymphoid… 
2014
2014
Abstract 4623: HDAC6 inhibition is a novel strategy to selectively impact inflammatory breast cancer cell survival
Inflammatory breast cancer (IBC) is a lethal and understudied variant of breast cancer, presenting with a signature clinical… 
2012
2012
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor Rocilinostat (ACY-1215) and Bortezomib, Demonstrates Synergistic Antitumor Activity in Preclinical Models of Lymphoma
Abstract 1650 The emergence of epigenetic therapies has identified histone deacetylase(HDAC) inhibitors as effective therapeutic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)